Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin

Yao Yu Hsieh, Chueh Chuan Yen, Chun Nan Yeh, Chin Yuan Tzen, Jin Hwang Liu, Hui Ju Lee, Hao Wei Teng, Cheng Hwai Tzeng, Tzeon Jye Chiou, Ta Chung Chao

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Here we presented a 60-year-old Taiwanese man with advanced gastrointestinal stromal tumor. Disease progression was noted during imatinib treatment. Surgical resection was done and mutation analysis of KIT gene in all the resected tumors revealed deletion mutations of codons 558-565 in exon 11, whereas a missense mutation was also identified at codon 822 in exon 17 in one resected tumor. Patient's disease was refractory to escalating dose of imatinib and dasatinb. Surprisingly, combination of imatinib with pegylated liposomal doxorubicin produced a substantial response and resulted in a 5-month progression free period for this imatinib-resistant gastrointestinal stromal tumor.

Original languageEnglish
Pages (from-to)272-274
Number of pages3
JournalJournal of the Chinese Medical Association
Volume74
Issue number6
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

Keywords

  • GIST
  • Imatinib-resistant
  • Kit mutation
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin'. Together they form a unique fingerprint.

Cite this